XENON PHARMACEUTICALS INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
XENON PHARMACEUTICALS INC. (XENE) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $6.48 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2024-02-29
- XENON PHARMACEUTICALS INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $6.48M, a 45.24% increase from fiscal 2022.
- XENON PHARMACEUTICALS INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was $4.46M, a 119.53% increase from fiscal 2021.
- XENON PHARMACEUTICALS INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2021 was $2.03M, a 79.12% increase from fiscal 2020.
- XENON PHARMACEUTICALS INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2020 was $1.14M, a 137.95% increase from fiscal 2019.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2023-12-31 | $6.48M 10-K · filed 2024-02-29 |
| 2022-12-31 | $4.46M 10-K · filed 2024-02-29 |
| 2021-12-31 | $2.03M 10-K · filed 2024-02-29 |
| 2020-12-31 | $1.14M 10-K · filed 2023-03-01 |
| 2019-12-31 | $477.00K 10-K · filed 2021-03-01 |
| 2018-12-31 | -$472.00K 10-K · filed 2020-03-09 |
| 2015-12-31 | $977.00K 10-K · filed 2016-03-08 |
| 2014-12-31 | -$1.05M 10-K · filed 2016-03-08 |
| 2013-12-31 | -$374.00K 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |